Combined, these data provide evidence that losartan does not modulate TGF-β activation in mild or severe models of dysferlinopathy and that classical pathways responsible for muscle homeostasis (protein synthesis and degradation) were not impacted by losartan despite significant muscle atrophy. This evidence concerns the gene TGFB1 and neuromuscular disease caused by qualitative or quantitative defects of dysferlin.